The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO WCGIC 2023 | Advances in FGFR inhibition for hepatobiliary cancer
Arndt Vogel, MD, Hannover Medical School, Hannover, Germany, discusses the latest developments in FGFR inhibition for patients with hepatobiliary cancer. The phase 2 FIGHT-202 trial (NCT02924376) of pemigatinib demonstrated survival benefit in patients with previously treated advanced cholangiocarcinoma, and futibatinib has been approved by the FDA for FGFR2-mutant cholangiocarcinoma. RLY-4008 is another highly selective, potent FGFR2 inhibitor, which can reduce off-target toxicity. This interview took place at the ESMO World Congress on Gastrointestinal Cancer (WCGIC) 2023 in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
